Could genetic testing for prostate cancer transform routine care? a study asks patients and doctors

NCT ID NCT07741929

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study explores how patients and healthcare providers view the use of genetic risk profiling for prostate cancer in everyday clinical practice. Through interviews, researchers aim to understand the benefits, challenges, and needs associated with receiving and delivering genetic risk results. The findings may help guide how such testing could be better integrated into routine care, ensuring it is practical and supportive for all involved.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Qualitative interviews
What this could lead to
If successful, this study could help shape how genetic risk profiling for prostate cancer is integrated into routine clinical care, improving patient education, support, and clinical guidelines.
What could go wrong
This is a small, interview-based study, so its findings may not represent all perspectives. It does not test a treatment or intervention, so it cannot directly change patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The Royal Marsden Hospital (Sutton and Chelsea)

    RECRUITING

    London, SM2 5PT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.